# DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

> **NCT04014075** · PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 79 (actual)

## Conditions studied

- Adenocarcinoma Gastric Stage IV With Metastases
- Adenocarcinoma - GEJ

## Interventions

- **DRUG:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT04014075
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-26
- **Primary completion:** 2021-11-08
- **Final completion:** 2024-02-13
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04014075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04014075, "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04014075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*